XI Yu-meng, LU Yu, HE Xiao-ming, YANG Shao-kun, ZHANG Jia, YANG Jian-kai, HE Chao-xing, XIANG Bai. Application of PDX model in the evaluation of nano-delivery systemsJ. Acta Pharmaceutica Sinica, 2023, 58(2): 330-338. DOI: 10.16438/j.0513-4870.2022-0720
Citation: XI Yu-meng, LU Yu, HE Xiao-ming, YANG Shao-kun, ZHANG Jia, YANG Jian-kai, HE Chao-xing, XIANG Bai. Application of PDX model in the evaluation of nano-delivery systemsJ. Acta Pharmaceutica Sinica, 2023, 58(2): 330-338. DOI: 10.16438/j.0513-4870.2022-0720

Application of PDX model in the evaluation of nano-delivery systems

  • Malignant tumor is a major disease affecting human health. The nano-delivery system itself has a unique size effect and it can achieve tumor-targeted distribution of drug molecules, improve the therapeutic effect, and reduce the toxic and side effects on normal tissues and cells after functional modification. Patient-derived xenografts (PDX) models can be established by transplanting patient-derived cancer cells or small tumor tissue into immunodeficient mice directly. Compared with the tumor cell line model, this model can preserve the key features of the primary tumor such as histomorphology, heterogeneity, and genetic abnormalities, and keep them stable between generations. PDX models are widely used in drug evaluation, target discovery and biomarker development, especially providing a reliable research platform for the diagnosis and treatment evaluation of nano-delivery systems. This review summarizes the application of several common cancer PDX models in the evaluation of nano-delivery systems, in order to provide references for researchers to perform related research.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return